Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Relevium Medical has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 action is assigned to 1 distinct examiner and 1 distinct art unit. This indicates a highly focused prosecution profile, with all current active matters residing within a single technical specialty at the patent office. This concentration allows for a specialized approach but also means the company's immediate patent success is tied to a narrow administrative channel within the biotechnology department.
The busiest examiner for this portfolio is RAHMANI, NILOOFAR, who is responsible for 1 pending office action. Since there is only 1 pending action in total, this examiner manages the entire active portfolio. For practitioners, this means that the immediate success of the company's patent efforts is tied to the specific examination practices of this 1 examiner and the standards of the 1 art unit. Success in this matter will require a deep understanding of the specific examination style and previous rulings associated with this 1 official, as there are no other active matters to provide alternative paths to allowance. The strategy must be precisely aligned with the examiner's historical preferences to ensure a successful result for the company's medical technology.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAHMANI, NILOOFAR | 1 | 77.6% | -2.9% |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18475687 | Analgesic Therapeutics Based on conjugation of Biocompatible Polymers to Ion Channel Modulators | RAHMANI, NILOOFAR | 1691 | §103 | Final Rejection | — | Pending | Sep 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRelevium Medical has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Niloofar Rahmani has the most, with 1 of Relevium Medical's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
